Evaluation of the Potential Impact of a High-fat Meal on the Pharmacokinetics of CRS3123 in Healthy Adult Participants

Phase 1 Completed 17 enrolled Crestone, Inc National Institute of Allergy and Infectious Diseases (NIAID) · collab

RandomizedCrossoverOpen-labelBasic science

Summary

This study will explore the potential effects of high-fat meal on the plasma pharmacokinetics (PK) of CRS3123 when administered as a single oral dose of 200 mg in healthy adult participants.

Timeline

Start: 2025-04-21
Primary completion: 2025-06-04
Completion: 2025-06-04

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	CRS3123	Small molecule	200 mg	Oral

Indications

No indication recorded.